Chorea as a non-thrombotic manifestation in an adolescent with systemic lupus erythematosus, antiphospholipid syndrome and heterozygous prothrombin G20210A gene mutation: a case report

Introduction: Chorea is a rare movement disorder in the context of systemic lupus erythematosus (SLE). Although basal ganglia thrombosis, autoimmune injury or neuronal direct lesion have been proposed as possible explanations, its mechanism is still unknown. It is important to understand its pathogenesis so that the best treatments can be identified. Case presentation: A 12-year-old female adolescent with choreoathetoid movements of the trunk and four limbs, slurred speech, hypophonia and orofacial dyskinesia with 14 days of evolution. Brain magnetic resonance imaging revealed recent subcortical ischemic lesions in both frontal and parietal lobes. Basal ganglia lesions were not found. She started acetylsalicylic acid (ASA) and tetrabenazine, with chorea improvement. Transcranial Doppler ultrasound identified a microembolic sign between the left middle cerebral and anterior cerebral arteries. Therefore, ASA was switched to enoxaparin. Antinuclear antibodies and lupus anticoagulant (LAC) antibody were positive, with heterozygous prothrombin G20210A gene mutation being found. Five-day methylprednisolone pulses 1g/day were performed, followed by prednisolone 60mg/day. Intravenous immunoglobulin was administered, and hydroxychloroquine was initiated. Due to progressive microscopic hematuria and non-nephrotic proteinuria, kidney biopsy was performed, being compatible with class V lupus nephritis. Consequently, mycophenolate mofetil and enalapril were started. Chorea resolved five days later. After discharge, LAC remained positive, but no more neurologic symptoms occurred. Conclusions: Basal ganglia thrombosis does not seem to be the most likely mechanism of SLE-related chorea. Antiphospholipid antibodies alone do not seem to be enough to trigger chorea. Further studies are needed to clarify the mechanisms that trigger this movement disorder.

Authors

Publication Details

Journal
Case Reports in Neurology
Published
2026-05-18
DOI
https://doi.org/10.1159/000552585
Primary Topic
Neurological and metabolic disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Chorea as a non-thrombotic manifestation in an adolescent with systemic lupus erythematosus, antiphospholipid syndrome and heterozygous prothrombin G20210A gene mutation: a case report

Inês Madureira, Carla Conceição, Carla Mendonça, Rosa Amorim-Figueiredo et al.
Case Reports in Neurology
Neurological and metabolic disorders
article

Chorea as a non-thrombotic manifestation in an adolescent with systemic lupus erythematosus, antiphospholipid syndrome and heterozygous prothrombin G20210A gene mutation: a case report

Inês Madureira, Carla Conceição, Carla Mendonça, Rosa Amorim-Figueiredo, Teresa Morais, Rita Lopes da Silva
article en

Abstract

Introduction: Chorea is a rare movement disorder in the context of systemic lupus erythematosus (SLE). Although basal ganglia thrombosis, autoimmune injury or neuronal direct lesion have been proposed as possible explanations, its mechanism is still unknown. It is important to understand its pathogenesis so that the best treatments can be identified. Case presentation: A 12-year-old female adolescent with choreoathetoid movements of the trunk and four limbs, slurred speech, hypophonia and orofacial dyskinesia with 14 days of evolution. Brain magnetic resonance imaging revealed recent subcortical ischemic lesions in both frontal and parietal lobes. Basal ganglia lesions were not found. She started acetylsalicylic acid (ASA) and tetrabenazine, with chorea improvement. Transcranial Doppler ultrasound identified a microembolic sign between the left middle cerebral and anterior cerebral arteries. Therefore, ASA was switched to enoxaparin. Antinuclear antibodies and lupus anticoagulant (LAC) antibody were positive, with heterozygous prothrombin G20210A gene mutation being found. Five-day methylprednisolone pulses 1g/day were performed, followed by prednisolone 60mg/day. Intravenous immunoglobulin was administered, and hydroxychloroquine was initiated. Due to progressive microscopic hematuria and non-nephrotic proteinuria, kidney biopsy was performed, being compatible with class V lupus nephritis. Consequently, mycophenolate mofetil and enalapril were started. Chorea resolved five days later. After discharge, LAC remained positive, but no more neurologic symptoms occurred. Conclusions: Basal ganglia thrombosis does not seem to be the most likely mechanism of SLE-related chorea. Antiphospholipid antibodies alone do not seem to be enough to trigger chorea. Further studies are needed to clarify the mechanisms that trigger this movement disorder.

Case Reports in Neurology
Good health and well-being, Gender equality
Openalex Percentile: Top 6%
Neurological and metabolic disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Chorea as a non-thrombotic manifestation in an adolescent with systemic lupus erythematosus, antiphospholipid syndrome and heterozygous prothrombin G20210A gene mutation: a case report — Inês Madureira, Carla Conceição, et al. · Case Reports in Neurology (2026) | TGRS Research Map | TGRS